N01.3 Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis

Name of the Condition

• Rapidly Progressive Nephritic Syndrome with Diffuse Mesangial Proliferative Glomerulonephritis
• ICD-10 Code: N01.3

Summary

Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis is a severe kidney disorder characterized by rapid loss of kidney function due to inflammation and proliferation of mesangial cells in the glomeruli, the kidney's filtering units. This condition presents with hematuria (blood in urine), proteinuria (excess protein in urine), and a swift decline in renal function, often progressing to acute kidney injury within weeks. Urgent diagnosis and treatment are essential to prevent irreversible damage.

Causes

The condition is typically driven by immune-mediated damage to the glomeruli, which may result from autoimmune diseases (such as lupus or vasculitis), infections, or exposure to certain medications. In some cases, the underlying cause remains idiopathic (unknown), but the aggressive progression distinguishes it from other forms of nephritic syndrome.

Risk Factors

• Autoimmune conditions: Diseases like systemic lupus erythematosus or vasculitis.
• Infections: Recent bacterial or viral infections that trigger immune responses.
• Medications: Use of drugs known to induce glomerular injury (e.g., certain antibiotics or NSAIDs).
• Genetic predisposition: Family history of kidney disease or autoimmune disorders.

Symptoms

• Hematuria (visible or microscopic blood in urine).
• Proteinuria (foamy or frothy urine).
• Edema (swelling in the face, hands, or legs).
• Hypertension (high blood pressure).
• Oliguria (reduced urine output).
• Fatigue or malaise.

Diagnosis

Diagnosis involves urinalysis to detect blood and protein, blood tests to assess kidney function (e.g., creatinine, BUN), and a kidney biopsy to confirm diffuse mesangial proliferative glomerulonephritis. Imaging studies (e.g., ultrasound) may be used to evaluate kidney structure, and serologic tests may identify underlying autoimmune or infectious causes.

Treatment Options

Treatment focuses on addressing the underlying cause and slowing disease progression. This may include immunosuppressive medications (e.g., corticosteroids, cyclophosphamide), plasmapheresis, or dialysis for severe cases. Blood pressure management and dietary modifications (e.g., low-sodium, protein-restricted diet) are also critical.

Prognosis and Follow-Up

Prognosis depends on the speed of diagnosis and response to treatment. Early intervention improves outcomes, but some patients may progress to chronic kidney disease or require long-term dialysis. Regular follow-up with kidney function monitoring and medication adjustments is essential.

Complications

• Acute kidney injury or failure.
• Chronic kidney disease.
• Hypertension.
• Edema-related complications (e.g., pulmonary edema).
• Increased risk of infections due to immunosuppressive therapy.

Lifestyle & Prevention

• Manage underlying conditions (e.g., autoimmune diseases) with medical supervision.
• Avoid nephrotoxic medications (e.g., NSAIDs) unless prescribed.
• Maintain a balanced diet low in sodium and protein.
• Stay hydrated and monitor urine output for changes.
• Seek prompt treatment for infections.

When to Seek Professional Help

Consult a healthcare provider immediately if you experience:

• Visible blood in urine.
• Sudden swelling (edema) in the legs, hands, or face.
• Severe fatigue or confusion.
• Reduced urine output.
• Chest pain or shortness of breath (signs of fluid overload).

Tips for Medical Coders

Document the presence of diffuse mesangial proliferative glomerulonephritis confirmed by biopsy to support the N01.3 code. Ensure clinical correlation with symptoms (e.g., hematuria, proteinuria) and rapid renal function decline. Include details of underlying causes (e.g., autoimmune, infectious) when available, as these may impact coding specificity. Avoid using this code for non-progressive or chronic forms of glomerulonephritis.